

MATERIALS LICENSE

Pursuant to the Atomic Energy Act of 1954, as amended, the Energy Reorganization Act of 1974 (Public Law 93-438), and Title 10, Code of Federal Regulations, Chapter I, Parts 30, 31, 32, 33, 34, 35, 36, 37, 39, 40, 70 and 71, and in reliance on statements and representations heretofore made by the licensee, a license is hereby issued authorizing the licensee to receive, acquire, possess, and transfer byproduct, source, and special nuclear material designated below; to use such material for the purpose(s) and at the place(s) designated below; to deliver or transfer such material to persons authorized to receive it in accordance with the regulations of the applicable Part(s). This license shall be deemed to contain the conditions specified in Section 183 of the Atomic Energy Act of 1954, as amended, and is subject to all applicable rules, regulations, and orders of the Nuclear Regulatory Commission now or hereafter in effect and to any conditions specified below.

<p style="text-align: center;">Licensee</p> <p>1. Alliance HealthCare Services, Inc.</p> <p>2. 330 Harper Park Drive, Suite C Beckley, WV 25801</p>	<p>In accordance with letter dated May 30, 2018.</p> <p>3. License number: 47-25570-01 is amended in its entirety to read as follows:</p>	<p>4. Expiration Date: September 30, 2021</p> <p>5. Docket No.: 030-35774 Reference No.:</p>
---	---	--

<p>6. Byproduct, source, and/or special nuclear material</p> <p>A. Any byproduct material permitted by 10 CFR 35.200</p>	<p>7. Chemical and/or physical form</p> <p>A. Any</p>	<p>8. Maximum amount that licensee may possess at any one time under this license</p> <p>A. As Needed</p>	<p>9. Authorized use</p> <p>A. For use in imaging and localization studies permitted by 10 CFR 35.200.</p>
--	---	---	--

CONDITIONS

10. Licensed material, limited to strontium/rubidium waste incident to mobile nuclear medicine activities, may be stored at the licensee's facilities located at 525 S. Gould Street, Owasso, Michigan, and licensed material incident to mobile nuclear medicine activities may be used or stored at temporary job sites of the licensee anywhere in the United States where the U.S. Nuclear Regulatory Commission maintains jurisdiction for regulating the use of licensed material, including areas of exclusive Federal jurisdiction within Agreement States.

If the jurisdiction status of a Federal facility within an Agreement State is unknown, the licensee should contact the Federal agency controlling the job site in question to determine whether the proposed job site is an area of exclusive Federal jurisdiction. Authorization for use of radioactive materials at job sites in Agreement States not under exclusive Federal jurisdiction shall be obtained from the appropriate state regulatory agency.

**MATERIALS LICENSE
SUPPLEMENTARY SHEET**

License Number
47-25570-01

Docket or Reference Number
030-35774

Amendment No. 18

11. Licensed material shall only be used by, or under the supervision of:

A. Individuals permitted to work as an authorized user in accordance with 10 CFR 35.13 and 10 CFR 35.14.

B. The following individuals are authorized users for the material and medical uses as indicated:

<u>Authorized User(M.D.,D.O.,etc.)</u>	<u>Material and Use</u>
Afzal Ahmed, M.D.	10 CFR 35.200
Marsha Anderson, M.D.	10 CFR 35.200
Marc R. Beck, M.D.	10 CFR 35.200
Martin Black, M.D.	10 CFR 35.200
Richard R. Black, D.O.	10 CFR 35.200
Rodger Blake, M.D.	10 CFR 35.200
Robert L. Bridges, M.D.	10 CFR 35.200
Tapan K. Chaudhuri, M.D.	10 CFR 35.200
Peter Chirico, M.D.	10 CFR 35.200
Jesse A. Cole, M.D.	10 CFR 35.200
Ricky J. Compton, M.D.	10 CFR 35.200
Michael T. Czuba, M.D.	10 CFR 35.200
Corinne Daurdulian, M.D.	10 CFR 35.200
Edward Dentsman, M.D.	10 CFR 35.200
Nathaniel D. Dueker, M.D.	10 CFR 35.200
Prasanta K. Karak, M.D.	10 CFR 35.200
Philip Kohanski, M.D.	10 CFR 35.200
Gary W. Kravetz, M.D.	10 CFR 35.200

**MATERIALS LICENSE
SUPPLEMENTARY SHEET**

License Number
47-25570-01

Docket or Reference Number
030-35774

Amendment No. 18

<u>Authorized User(M.D.,D.O.,etc.)</u>	<u>Material and Use</u>
Christopher J. Leary, M.D.	10 CFR 35.200
Timothy J. McCue, M.D.	10 CFR 35.200
Khalid A. Mian, M.D.	10 CFR 35.200
Thomas E. Miller, M.D.	10 CFR 35.200
Eric Netland, M.D.	10 CFR 35.200
Michael T. Oberhofer, M.D.	10 CFR 35.200
Dana Olson, M.D.	10 CFR 35.200
Bharat Patel, M.D.	10 CFR 35.200
Mark Peterson, M.D.	10 CFR 35.200
Ruben Rock, M.D.	10 CFR 35.200
Colin Rose, M.D.	10 CFR 35.200
Heather Rose, M.D.	10 CFR 35.200
Ronald J. Rosenberg, M.D.	10 CFR 35.200
Robert M. Salman, M.D.	10 CFR 35.200
Paul Sanchirico, M.D.	10 CFR 35.200
Walter Parke Thrush, M.D.	10 CFR 35.200
James K. Watson, M.D.	10 CFR 35.200

12. The Radiation Safety Officer for this license is Kay Kassel, M.S., C.N.M.T.

13. In addition to the possession limits in Item 8, the licensee shall further restrict the possession of licensed material to quantities below the minimum limit specified in 10 CFR 30.35(d) for establishing decommissioning financial assurance.

**MATERIALS LICENSE
SUPPLEMENTARY SHEET**License Number
47-25570-01Docket or Reference Number
030-35774

Amendment No. 18

14. Except as specifically provided otherwise in this license, the licensee shall conduct its program in accordance with the statements, representations, and procedures contained in the documents, including any enclosures, listed below. This license condition applies only to those procedures that are required to be submitted in accordance with the regulations. Additionally, this license condition does not limit the licensee's ability to make changes to the radiation protection program as provided for in 10 CFR 35.26. The U.S. Nuclear Regulatory Commission's regulations shall govern unless the statements, representations, and procedures in the licensee's application and correspondence are more restrictive than the regulations.

- A. Application dated April 5, 2011 [ML110970462]
- B. Letter dated August 31, 2011 [ML112440261]
- C. Document received on September 12, 2011 (delegation of authority) [ML112620433]
- D. Letter dated June 19, 2015 [ML15195A190]
- E. Letter dated October 13, 2015 [ML15292A554]
- F. Letter dated January 4, 2016 [ML16022A219]
- G. Letter dated January 12, 2016 [ML16022A229]
- H. Letter dated August 23, 2018 w/attachments

FOR THE U.S. NUCLEAR REGULATORY COMMISSION

Date: August 29, 2018By: Penny Lanzisera
Region 1